Filtered By:
Cancer: Brain Cancers
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 2156 results found since Jan 2013.
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cerebrovascular accident in a child with precursor B-cell acute lymphoblastic leukemia and coronavirus disease 2019: a case report
ConclusionOwing to the link between coronavirus disease 2019 and hematologic cancers with hypercoagulopathy and the tendency of patients with leukemia to have coronavirus disease 2019 complications, children with leukemia as well as suspected coronavirus disease 2019 must be hospitalized to prevent blood clot formation.
Source: Journal of Medical Case Reports - December 6, 2022 Category: General Medicine Source Type: research
Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases
This article completes the first part, in which we presented the interest of NfL in the context of neurodegenerative diseases. Here we focus our review on other clinical contexts of neurological injury (such as traumatic brain injury, multiple sclerosis, stroke, and cancer) and present the potential value of NfL assay in the management of these patients, for both diagnosis and prognosis. We also discuss the added value of the NfL assay compared to other biomarkers commonly used in the described clinical situations.PMID:36453743 | DOI:10.1684/abc.2022.1758
Source: Annales de Biologie Clinique - December 1, 2022 Category: Biochemistry Authors: Constance Delaby Olivier Bousiges Damien Bouvier Catherine Fill ée Anthony Fourier Étienne Mondésert Nicolas Nezry Souheil Omar Isabelle Quadrio Benoit Rucheton Susanna Schraen-Maschke Vincent van Pesch St éphanie Vicca Sylvain Lehmann Aur élie Bedel Source Type: research
Neuro faces of beneficial T cells: essential in brain, impaired in aging and neurological diseases, and activated functionally by neurotransmitters and neuropeptides
Neural Regen Res. 2023 Jun;18(6):1165-1178. doi: 10.4103/1673-5374.357903.ABSTRACTT cells are essential for a healthy life, performing continuously: immune surveillance, recognition, protection, activation, suppression, assistance, eradication, secretion, adhesion, migration, homing, communications, and additional tasks. This paper describes five aspects of normal beneficial T cells in the healthy or diseased brain. First, normal beneficial T cells are essential for normal healthy brain functions: cognition, spatial learning, memory, adult neurogenesis, and neuroprotection. T cells decrease secondary neuronal degeneration,...
Source: Cell Research - December 1, 2022 Category: Cytology Authors: Mia Levite Source Type: research
Neurofilaments: a key new biomarker for clinicians. Part 2: Neurofilaments, an asset beyond neurodegenerative diseases
This article completes the first part, in which we presented the interest of NfL in the context of neurodegenerative diseases. Here we focus our review on other clinical contexts of neurological injury (such as traumatic brain injury, multiple sclerosis, stroke, and cancer) and present the potential value of NfL assay in the management of these patients, for both diagnosis and prognosis. We also discuss the added value of the NfL assay compared to other biomarkers commonly used in the described clinical situations.PMID:36453743 | DOI:10.1684/abc.2022.1758
Source: Annales de Biologie Clinique - December 1, 2022 Category: Biochemistry Authors: Constance Delaby Olivier Bousiges Damien Bouvier Catherine Fill ée Anthony Fourier Étienne Mondésert Nicolas Nezry Souheil Omar Isabelle Quadrio Benoit Rucheton Susanna Schraen-Maschke Vincent van Pesch St éphanie Vicca Sylvain Lehmann Aur élie Bedel Source Type: research
